Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv
Top Research Reports for Toyota, Netflix & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor (TM), Netflix (NFLX) and AbbVie (ABBV).
Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Biotech ETFs in Focus on Impressive Q3 Earnings Results
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.
The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG
Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More
by Zacks Equity Research
Key highlights include earnings updates, collaboration deals, and regulatory and pipeline updates.
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
Callaway Golf, FedEx, Amazon, Intel and Gilead highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Callaway Golf, FedEx, Amazon, Intel and Gilead highlighted as Zacks Bull and Bear of the Day
Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat
by Zacks Equity Research
Gilead (GILD) falls short of earnings estimates but marginally beats on sales in the third quarter of 2019.
Q3 Earnings Frenzy: Amazon (AMZN), Intel (INTC) & More
by Mark Vickery
Amazon missed earnings estimates, while Intel beat again and Gilead was in-line with expectations.
Gilead Sciences (GILD) Misses Q3 Earnings Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -0.57% and 0.10%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Gilead (GILD) Might Surprise This Earnings Season
by Zacks Equity Research
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: U.S. Bancorp, Bristol-Myers Squibb, Morgan Stanley, Bank of America and Gilead Sciences
Will Strong Jakafi Sales Drive Incyte's (INCY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2019 results.
Top Stock Reports for U.S. Bancorp, Bristol-Myers Squibb & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including U.S. Bancorp (USB), Bristol-Myers Squibb (BMY) and Morgan Stanley (MS).
Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
What's in Store for Healthcare ETFs in Q3 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings?
by Zacks Equity Research
During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.
Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.
Factors Setting the Tone for Novartis' (NVS) Q3 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $65.23, marking a -0.18% move from the previous day.
Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth
The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar